Head-to-head evidence
Elsulfavirine vs Tenofovir alafenamide/emtricitabine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Elsulfavirine · Elpida
Marketed by Viriom
NCT02489461 · Phase 2/3 · completed
The study randomized 150 participants and used double blinding with an active efavirenz comparator. Its primary endpoint was the proportion with HIV-1 RNA below 400 copies/mL at Week 12, but no results are posted, so the outcome comparison cannot be assessed.
Tenofovir alafenamide/emtricitabine · Descovy
Marketed by Gilead Sciences
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07349758 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elsulfavirine's landscape · Tenofovir alafenamide/emtricitabine's landscape